- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01098006
A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays
Przegląd badań
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Brussels, Belgia, 1070
- GSK Investigational Site
-
Bruxelles, Belgia, 1000
- GSK Investigational Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Written informed consent obtained from the subject.
- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
- A male or female between, and including, 18 and 65 years of age at study start.
- Evidence of chronic hepatitis B infection as per medical record.
- Female subjects of non-childbearing potential may be enrolled in the study.
- Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.
In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:
Group A: Immune tolerant patients
- Viral load: > 2x107 IU/mL of HBV DNA
- HBeAg positive
- Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients
- Viral load: > 2x104 IU/mL of HBV DNA
- HBeAg positive
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C: Healthy carriers
- Viral load: not exceeding 2x103 IU/mL of HBV DNA
- HBeAg negative
- Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients
- Viral load: > 2x103 IU/mL of HBV DNA
- HBeAg negative
- Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy
Exclusion Criteria:
- Any hepatitis B specific treatment prior to blood sampling at Visit 1.
- Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.
- Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.
- Receipt of blood products within 120 days prior to study entry (Visit 1).
- Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).
- Receipt of interferon within 120 days prior to study entry (Visit 1).
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).
- Pregnant or lactating female.
- History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone ≥10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.
- History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).
- History of major congenital defect.
- Subjects with a history of, or current, alcohol or substance abuse.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Inny: Immune tolerant patients Group
Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Inny: HBeAg positive Group
HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Inny: Inactive carriers Group
Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Inny: HBeAg negative Group
HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
|
A single blood sample was to be taken from all subjects at the study visit.
No study-related treatment was given to the study participants.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.
|
At the time of the visit for each subject (i.e., Day 0)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples
Ramy czasowe: At the time of the visit for each subject (i.e., Day 0)
|
The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17. Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001). |
At the time of the visit for each subject (i.e., Day 0)
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Układu Pokarmowego
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby wątroby
- Zapalenie wątroby, wirusowe, ludzkie
- Infekcje Hepadnaviridae
- Infekcje wirusami DNA
- Zapalenie wątroby typu B
- Zapalenie wątroby
- Wirusowe zapalenie wątroby typu B, przewlekłe
- Zapalenie wątroby, przewlekłe
Inne numery identyfikacyjne badania
- 113854
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Blood withdrawal
-
Applied Science & Performance InstituteZakończonyNiedobór żelaza (bez niedokrwistości)Stany Zjednoczone
-
Ischemia Care LLCZakończonyUdar niedokrwienny | Migotanie przedsionków | Udar zakrzepowy | Przejściowe ataki niedokrwienne | Udar sercowo-zatorowy | Udar tętnicy podstawnej | Przejściowe zdarzenia naczyniowo-mózgoweStany Zjednoczone
-
George Fox UniversityNieznanySłabe mięśnie | Czy terapia ograniczająca przepływ krwi zwiększa wzrost siły w mankiecie rotatorówStany Zjednoczone
-
Christopher BellZakończonyĆwiczenie wytrzymałościoweStany Zjednoczone
-
Reham HassanZakończonyWpływ elementówEgipt
-
University Hospital, Clermont-FerrandCentre Jean PerrinNieznanyKwantyfikacja spoczynku/stresu dyssynchronii lewej komory za pomocą bramkowanej puli krwi 3D D-SPECTDyssynchronia lewej komoryFrancja
-
University of Maryland, BaltimoreZakończonyNie-anemiczny niedobór żelazaStany Zjednoczone
-
Aktiia SARekrutacyjny
-
Changi General HospitalZakończonyKrwotok | Powikłania związane z cewnikiem | Dializa; Komplikacje | Powikłanie rany | Krwawiąca RanaSingapur